Drug Trial Radar · NCT06049810
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
566
Actual
Start
Oct 10, 2023
Primary completion
Apr 29, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in the treatment of participants with moderate to severe psoriasis
Conditions
- Psoriasis
Interventions
IBI112Drug
Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
IBI112/placeboDrug
Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
IBI112/placeboDrug
Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
IBI112Drug
Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
IBI112Drug
Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
IBI112Drug
Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 ResponseTime frame: Week 56
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.